Thus, the rapid development of a7nAChR agonists, such as GTS-21 and GAT107, which has already been evaluated for the treatment of certain neurodegenerative diseases, could be beneficial for patients with pulmonary infections, such as VAP and COVID-19 [86]. This evidence concerns the gene CHRNA7 and ventilator-associated pneumonia.